Obesity in Heart Disease


A Statement for Healthcare Professionals From the Nutrition Committee, American Heart Association

Robert H. Eckel, MD, For the Nutrition Committee

Footnotes

Obesity is an increasingly prevalent metabolic disorder affecting not only the US population but also that of the developing world. It is estimated from the third National Health and Nutrition Examination Survey (NHANES III) (1988-1991) that 33% of the US population is obese, compared with 25% in NHANES II (1976-1980).1 Fatness is associated with a number of comorbidities, including several forms of heart disease. Although heredity explains 30% to 70% of cases of obesity, environmental contributions to the increasing prevalence of obesity must be sought since the gene pool has remained stable over the same interval. Diets high in fat (and calories)2 and a reduced expenditure of energy in the form of physical activity3 are the most likely explanations. However, in the United States, despite the reduction in consumption of fat from approximately 40% of calories in 1965 to 34% of calories in 1991,4 a decrease in incidence of obesity has not occurred. This is likely attributable to both maintenance of fat intake with an increase in total caloric intake and reduced physical activity. Interestingly, in developing countries some comorbidities are seen at a lesser degree of excess weight, suggesting that relative weight may be as important as absolute adiposity.

Definition of Obesity

The definition of obesity, or being overweight,5 remains controversial. In the United States, mortality data provided by the Metropolitan Life Insurance Company historically have been used to define obesity.6 Yet these data relate to mortality only, and the definition depends on a person's frame (size), which is arbitrary and not independently related to obesity-related mortality or comorbidities. Body mass index (BMI) has recently gained favor as a better measure of adiposity.7,8 BMI is defined as weight in kilograms divided by height in meters squared (kg/m2). A threshold level of BMI to define obesity is not entirely appropriate because in women, a BMI <21 may be associated with the greatest protection from coronary heart disease mortality.9 Yet for many women a BMI near 30 may still not be of concern when the increase in adipose tissue is distributed in the pelvis and not the abdomen. Substantial evidence now indicates that an increased waist circumference, or waist-to-hip ratio, predicts comorbidities and mortality from obesity.10,11 Unfortunately, a BMI-based definition fails to take body fat distribution into account.

Obesity and Coronary Heart Disease

Until recently the relation between obesity and coronary heart disease was viewed as indirect, ie, through covariates related to both obesity and coronary heart disease risk,12 including hypertension; dyslipidemia, particularly reductions in HDL cholesterol; and impaired glucose tolerance or non-insulin-dependent diabetes mellitus. Insulin resistance and accompanying hyperinsulinemia are typically associated with these comorbidities.13 Although most of the comorbidities relating obesity to coronary artery disease increase as BMI increases, they also relate to body fat distribution. Long-term longitudinal studies, however, indicate that obesity as such not only relates to but independently predicts coronary atherosclerosis.9,14,15 This relation appears to exist for both men and women with minimal increases in BMI. In a 14-year prospective study, middle-aged women with a BMI >23 but <25 had a 50% increase in risk of nonfatal or fatal coronary heart disease,9 and men aged 40 to 65 years with a BMI >25 but <29 had a 72% increased risk.16 The overall relation between obesity and coronary artery disease morbidity and mortality is less clear for Hispanics,17 Pima Indians,18 and African-American women.19

Congestive Heart Failure

Left ventricular hypertrophy is common in patients with obesity and to some extent is related to systemic hypertension.20 However, abnormalities in left ventricular mass and function also occur in the absence of hypertension21 and may be related to the severity of obesity.22 Hypertension is approximately three times more common in obese than normal-weight persons.23 This relationship may be cause-and-effect in that when weight increases, so does blood pressure,24 whereas when weight decreases, blood pressure falls.25

Increased left ventricular volume and wall stress in addition to increased stroke volume and cardiac output are commonly seen in systemic hypertension.21,26 The hypertrophy of the left ventricle is both concentric and eccentric, and diastolic dysfunction is common. When obesity is present but systemic hypertension is absent, left ventricular volume is often increased, but wall stress usually remains normal. However, in obese patients without hypertension, increases in stroke volume and cardiac output as well as diastolic dysfunction are seen. These changes in the left ventricle are related to sudden death in obese patients. When 22 patients with severe obesity were examined postmortem, dilated cardiomyopathy was most frequently associated with sudden death (n=10), with severe coronary atherosclerosis (n=6), concentric left ventricular hypertrophy without dilatation (n=4), pulmonary embolism (n=1), and hypoplastic coronary arteries (n=1) also found.22 Thus, dilated cardiomyopathies, presumably with concomitant cardiac arrhythmias, may be the most common cause of sudden death in patients with severe obesity. The prolonged QT interval also seen in obesity27 may predispose to such arrhythmias.

Changes in the right heart also occur in obesity. The pathophysiology is related to obstructive sleep apnea and/or the obesity hypoventilation syndrome, which produce pulmonary hypertension and right ventricular hypertrophy, dilatation, progressive dysfunction, and finally failure.28,29 However, right ventricular dysfunction can also occur as a consequence of left ventricular dysfunction, and the heart failure that develops is often biventricular.21

Treatment of Obesity and Heart Disease

In patients with congestive heart failure, sodium restriction and small reductions in weight may dramatically improve ventricular function and oxygenation.30,31 In addition, several studies suggest that the more extensive weight reduction that follows gastrointestinal surgery for obesity reduces cardiovascular mortality32 and in persons with non-insulin-dependent diabetes, both cardiovascular and total mortality.33 Moreover, although many studies have demonstrated the beneficial effects of weight reduction on cardiovascular risk factors such as hypertension25,34,35 and dyslipidemia,36,37 recent studies from Sweden indicate that the major reduction of body weight that follows gastrointestinal surgery for obesity also reduces incidence of non-insulin-dependent diabetes mellitus.38 Shortening of the QT interval also follows weight reduction.39 Thus, weight reduction appears efficacious in reducing risks of coronary heart disease and congestive heart failure and potentially preventing heart disease in obese patients.

Treatment of obesity should be based on its severity and the presence of comorbidities, eg, congestive heart failure, dyslipidemia, hypertension, non-insulin dependent diabetes, and obstructive sleep apnea. Maintaining a BMI <25 throughout adult life has been recently recommended.40 For most patients with a BMI between 25 and 30, lifestyle modifications including diet and exercise are appropriate. Diets should be modestly restricted in calories; evidence suggests that obese patients who have slower rates of weight reduction have the same long-term outcomes as patients undergoing more rapid weight reduction.41 Restricting consumption of fat to <30% of total calories should also be prescribed because low-fat diets may also promote weight reduction.42 When rapid weight loss is needed, eg, for severe biventricular heart failure, more severe caloric restriction, eg, <=800 calories daily, with at least 0.75 g/kg bioavailable protein, can be used.43 For less-urgent weight reduction, a loss of 0.45 kg (1 lb) per week is reasonable.44 This rate of weight loss would require a caloric deficit of about 400 calories per day.

Training programs that increase physical activity have had a variable effect on body mass and composition.45,46 However, simply changing daily routines, eg, parking farther away and using the stairs rather than the elevator, may also be effective.47 Once weight loss has been achieved, a more vigorous exercise program may also enhance maintenance of reduction in weight.48

Pharmaceuticals should be considered with a BMI >30 or with less-severe obesity and comorbidities.49,50 The rationale for use and discussion with the patient about adverse effects of the medications should be documented in the patient's record. If the risk from obesity is sufficiently serious to indicate use of antiobesity drugs, long-term use should be anticipated. However, a case-control study in Europe demonstrated that patients treated with dexfenfluramine for more than 3 months had an odds ratio of 23.1 (95% confidence interval, 6.9 to 77.7) of developing primary pulmonary hypertension.51 A potential link between fenfluramine therapy of obese patients with valvular heart disease has also been raised.52 As a result, both fenfluramine and dexfenfluramine have been withdrawn from the market. Few drug choices remain. Like other nonsurgical therapies for obesity, once antiobesity drugs are discontinued, weight gain typically follows.53

When the BMI is >35 and comorbidities exist, gastrointestinal surgery becomes a consideration. When the BMI is >40, surgery is the treatment of choice. The experience of the surgeon and type of operation chosen predict outcome. In general, a Roux-en-Y gastric bypass is superior to gastric plication.54

Although weight reduction is not recommended for patients with a BMI <25, some patients in this category clearly have risks related to body fat distribution. Although measurement of waist circumference may help identify such patients, this assessment is crude, and other approaches are more expensive, ie, magnetic resonance imaging and computed tomography. Moreover, the radiation risk with some techniques (eg, computed tomography) precludes their use in children.

No matter what the therapeutic approach, it is important to realize that obesity is a disorder and recidivism is common, with <5% of patients maintaining their reduced weight at 4 years.55 Thus, therapeutic regimens must be maintained indefinitely; even then, only surgery has been proved to produce substantial sustained long-term weight loss. Prevention of obesity by diet and regular physical activity remains the highest priority for maintaining cardiovascular health. This is particularly important for small children and adolescents.

References

  1. Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among U.S. adults: the National Health and Nutrition Examination Survey. JAMA. 1994;272:205-211.
  2. Lissner L, Heitmann BL. Dietary fat and obesity: evidence from epidemiology. Eur J Clin Nutr. 1995;49:79-90.
  3. Williamson DF, Madans J, Anda RF, Kleinman JC, Kahn HS, Byers T. Recreational physical activity and ten-year weight change in a US national cohort. Int J Obes. 1993;17:279-286.
  4. Popkin BM, Siega-Riz AM, Haines PS. A comparison of dietary trends among racial and socioeconomic groups in the United States. N Engl J Med. 1996;335:716-720.
  5. Abernathy RP, Black DR. Healthy body weights: an alternative approach. Am J Clin Nutr. 1996;63:448S-451S.
  6. Metropolitan Life Insurance Company. Metropolitan height and weight tables. Stat Bull Met Life Ins Co. 1983;64:2.
  7. Kraemer H, Berkowitz RI, Hammer LD. Methodological difficulties in studies of obesity, I: measurement issues. Ann Behav Med. 1990;12:112-118.
  8. Must A, Dallal GE, Dietz WH. Reference data for obesity: 85th and 95th percentiles of body mass index (wt/ht2) and triceps skinfold thickness. Am J Clin Nutr. 1991;53:839-846.
  9. Manson JE, Willett WC, Stampfer MJ, Colditz GA, Hunter DJ, Hankinson SE, Hennekens CH, Speizer FE. Body weight and mortality among women. N Engl J Med. 1995;333:677-685.
  10. Lapidus L, Bengtsson C, Larsson B, Pennert K, Rybo E, Sjostrom L. Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the population study of women in Gothenburg, Sweden. BMJ. 1984;289:1257-1261.
  11. Larsson B, Svardsudd K, Welin L, Wilhelmsen L, Bjorntorp P, Tibblin G. Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913. BMJ. 1984;288:1401-1404.
  12. Lew EA, Garfinkel L. Variations in mortality by weight among 750,000 men and women. J Chronic Dis. 1979;32:563-576.
  13. Reaven GM. Banting lecture: role of insulin resistance in human disease. Diabetes. 1988;37:1595-1607.
  14. Garrison RJ, Castelli WP. Weight and thirty-year mortality of men in the Framingham Study. Ann Intern Med. 1985;103:1006-1009.
  15. Rabkin SW, Mathewson FA, Hsu PH. Relation of body weight to development of ischemic heart disease in a cohort of young North American men after a 26 year observation period: the Manitoba Study. Am J Cardiol. 1977;39:452-458.
  16. Rimm EB, Stampfer MJ, Giovannucci E, Ascherio A, Spiegelman D, Colditz GA, Willett WC. Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men. Am J Epidemiol. 1995;141:1117-1127.
  17. Stern MP, Patterson JK, Mitchell BD, Haffner SM, Hazuda HP. Overweight and mortality in Mexican Americans. Int J Obes. 1990;14:623-629.
  18. Pettitt DJ, Lisse JR, Knowler WC, Bennett PH. Mortality as a function of obesity and diabetes mellitus. Am J Epidemiol. 1982;115:359.
  19. Stevens J, Keil JE, Rust PF, Tyroler HA, Davis CE, Gazes PC. Body mass index and body girths as predictors of mortality in black and white women. Arch Intern Med. 1992;152:1257-1262.
  20. Messerli FH. Cardiovascular effects of obesity and hypertension. Lancet. 1982;1:1165-1168.
  21. Alpert MA, Hashimi MW. Obesity and the heart. Am J Med Sci. 1993;306:117-123.
  22. Duflou J, Virmani R, Rabin I, Burke A, Farb A, Smialek J. Sudden death as a result of heart disease in morbid obesity. Am Heart J. 1995;130:306-313.
  23. Van Itallie TB. Health implications of overweight and obesity in the United States. Ann Intern Med. 1985;103:983-988.
  24. Kannel WB, Brand N, Skinner JJ Jr, Dawber TR, McNamara PM. The relation of adiposity to blood pressure and development of hypertension: the Framingham study. Ann Intern Med. 1967;67:48-59.
  25. Reisin E, Frohlich ED, Messerli FH, Dreslinski GR, Dunn FG, Jones MM, Batson HM Jr. Cardiovascular changes after weight reduction in obesity hypertension. Ann Intern Med. 1983;98:315-319.
  26. Messerli FH, Aepfelbacher FC. Hypertension and left ventricular hypertrophy. Hypertension. 1995;13:549-557.
  27. Frank S, Colliver JA, Frank A. The electrocardiogram in obesity: statistical analysis of 1,029 patients. J Am Coll Cardiol. 1986;7:295-299.
  28. Burwell CS, Robin ED, Whaley RD, Bickelmann AG. Extreme obesity associated with alveolar hypoventilation. Am J Med. 1956;21:811.
  29. Menashe VD, Farrehi C, Miller M. Hypoventilation and cor pulmonale due to chronic upper airway obstruction. J Pediatr. 1965;67:198-203.
  30. Alexander JK. The cardiomyopathy of obesity. Prog Cardiovasc Dis. 1985;27:325-333.
  31. Estes EH Jr, Seider HO, McIntosh HD. Reversible cardiopulmonary syndrome with extreme obesity. Circulation. 1957;16:179-187.
  32. Matts JP, Buchwald H, Fitch LL, Campos CT, Varco RL, Campbell GS, Pearce MB, Yellin AE, Smink RD Jr, Sawin HS Jr, Long JM. Subgroup analyses of the major clinical endpoints in the program on the surgical control of the hyperlipidemias (Posch): overall mortality, atherosclerotic coronary heart disease (ACHD) mortality, and ACHD mortality or myocardial infarction. J Clin Epidemiol. 1995;48:389-405.
  33. McDonald KG, Long SD, Swanson MS, Brown BM, Morris P, Dohm GL, Pories WJ. The gastric bypass operation reduces the progression and mortality of non-insulin dependent diabetes mellitus. J Gastrointestinal Surg. 1997. In press.
  34. Scherrer U, Nussberger J, Torriani S, Waeber B, Dariolo R, Hofstetter JR, Brunner HR. Effect of weight reduction in moderately overweight patients on recorded ambulatory blood pressure and free cytosolic platelet calcium. Circulation. 1991;83:552-558.
  35. De Simone G, Mancini M, Mainenti G, Turco S, Ferrara LA. Weight reduction lowers blood pressure independently of salt restriction. J Endocrinol Invest. 1992;15:339-343.
  36. Rossner S, Bjorvell H. Early and late effects of weight loss on lipoprotein metabolism in severe obesity. Atherosclerosis. 1987;64:125-130.
  37. Zimmerman J, Kaufmann NA, Fainaru M, Eisenberg S, Oschry Y, Friedlander Y, Stein Y. Effect of weight loss on moderate obesity on plasma lipoprotein and apolipoprotein levels and on high density lipoprotein composition. Arteriosclerosis. 1984;4:115-123.
  38. Sjöström L. Obesity and weight change in relation to disease. Obes Res. 1996;4(suppl 1):3S.
  39. Carella MJ, Mantz SL, Rovner DR, Willis PW III, Gossain VV, Bouknight RR, Ferenchick GS. Obesity, adiposity, and lengthening of the QT interval: improvement after weight loss. Int J Obes. 1996;20:938-942.
  40. Meisler JG, St. Jeor S. Summary and recommendations from the American Health Foundation's Expert Panel on Healthy Weight. Am J Clin Nutr. 1996;63:474S-477S.
  41. Wadden TA, Goster GS, Letizia KA. One-year behavioral treatment of obesity: comparison of moderate and severe caloric restriction and the effects of weight maintenance therapy. J Consult Clin Psychol. 1994;62:165-171.
  42. Schaefer EJ, Lichtenstein AH, Lamon-Fava S, McNamara JR, Schaefer MM, Rasmussen H, Ordovas JM. Body weight and low-density lipoprotein cholesterol changes after consumption of a low-fat ad libitum diet. JAMA. 1995;274:1450-1455.
  43. Fisler JS. Cardiac effects of starvation and semistarvation diets: safety and mechanisms of action. Am J Clin Nutr. 1992;56:230S-234S.
  44. Subcommittee of Nutritionists for the American Heart Association Nutrition Committee. American Heart Association guidelines for weight management programs for healthy adults. Heart Dis Stroke. 1994;3:221-228.
  45. Hadjiolova I, Mintcheva L, Dunev S, Daleva M, Handjiev S, Balabanski L. Physical working capacity in obese women after an exercise programme for body weight reduction. Int J Obes. 1982;6:405-410.
  46. Hagen RD, Upton SJ, Wong L, Whittam J. The effects of aerobic conditioning and/or caloric restriction in overweight men and women. Med Sci Sports Exerc. 1986;18:87-94.
  47. Epstein LH, Valoski AM, Kalarchian MA, McCurley J. Do children lose and maintain weight easier than adults: a comparison of child and parent weight changes from six months to ten years. Obes Res. 1995;3:411-417.
  48. Ewbank PP, Darga LL, Lucas CP. Physical activity as a predictor of weight maintenance in previously obese subjects. Obes Res. 1995;3:257-263.
  49. National Task Force on the Prevention and Treatment of Obesity. Long-term pharmacotherapy in the management of obesity. JAMA. 1996;276:1907-1915.
  50. Pi-Sunyer X. Guidelines for the approval and use of obesity drugs. Obes Res. 1995;3:473-478.
  51. Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, Higenbottam T, Oakley C, Wouters E, Aubier M, Simonneau G, Begaud B. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med. 1996;335:609-616.
  52. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Schaff HV. Valvular heart disease associated with commonly prescribed diet pills. N Engl J Med. 1997;337:581-588.
  53. Weintraub M. Long-term weight control study. Clin Pharmacol Ther. 1992;51:581-643.
  54. Consensus statement: NIH Consensus Development Conference. Gastrointestinal surgery for severe obesity. Am J Clin Nutr. 1992;55:615-619.
  55. Kramer FM, Jeffery RW, Forster JL. Long-term follow-up of behavioral treatment for obesity: patterns of weight regain among men and women. Int J Obes. 1989;13:123-136.

 

 


"Obesity and Heart Disease" was approved by the American Heart Association Science Advisory and Coordinating Committee in August 1997.

A single reprint is available by calling 800-242-8721 (US only) or writing the American Heart Association, Public Information, 7272 Greenville Avenue, Dallas, TX 75231-4596. Ask for reprint No. 71-0130.

(Circulation. 1997;96:3248-3250.)

© 1997 American Heart Association, Inc.

 

© 1998 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited.

The information contained in this American Heart Association (AHA) Web site is not a substitute for medical advice or treatment, and the AHA recommends consultation with your doctor or health care professional.